ArticleImmunity, inflammation and disease2026
Early Mortality Following Systemic Anticancer Therapy in Lung Cancer: A Bayesian Spatiotemporal Multilevel Analysis.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early Mortality Following Systemic Anticancer Therapy in Lung Cancer: A Bayesian Spatiotemporal Multilevel Analysis.Immunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDespite advances in lung cancer treatment, early mortality following Systemic Anticancer Therapy (SACT) remains a major concern. Identifying patients at high risk of early mortality may inform treatment decision-making, particularly where SACT may offer limited benefit. We aimed to quantify spatiotemporal patterns of early mortality following SACT and to examine the relative contributions of individual- and area-level risk factors.
methodsWe conducted a secondary analysis of data from the Victorian Lung Cancer Registry. Bayesian spatiotemporal multilevel models were used to assess associations between individual- and area-level factors and early mortality following SACT. Adjusted Odds Ratios (AORs) with 95% Credible Interval (Crl) were reported to indicate statistical significance.
resultsSubstantial spatiotemporal variation in early mortality following SACT was observed across Victoria. Factors associated with increased odds of early mortality included age ≥ 60 years (AOR = 1.06, 95% Crl: 1.01-1.22), clinical stage II (AOR = 1.15, 95% Crl: 1.01-1.59), stage III (AOR = 1.28, 95% Crl: 1.01-2.05), stage IV (AOR = 3.19, 95% Crl: 2.12-5.07), comorbidity (AOR = 1.12, 95% Crl: 1.01-1.34), and poor performance status (AOR = 3.09, 95% Crl: 2.24-4.24). Presentation at a multidisciplinary meeting (AOR = 0.66, 95% Crl: 0.52-0.88) and receipt of supportive care screening (AOR = 0.53, 95% Crl: 0.41-0.69) were associated with reduced odds of early mortality.
conclusionMarked spatiotemporal variation in early mortality following SACT highlights the need for targeted, risk-informed treatment strategies, particularly for patients with advanced disease, comorbidities, poor performance status, and those residing in high-risk areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.